114081-67-3

Upstream product

• 100-46-9 benzylamine 
• 874-60-2 4-methyl-benzoyl chloride 
• 5436-83-9 N-benzyl-4-methylbenzamide 

Downstream Products

• 1430730-38-3 4-benzyl-5-(4-methylphenyl)-3-(2',3',4',6'-tetra-O-benzoyl-β-D-glucopyranosyl)-1,2,4-triazole 
• 1262150-84-4 C₂₉H₂₃N 
• 1218987-68-8 1-(tert-butylamino)-2-phenyl-4-p-tolylpyrimido[6,1-a]isoquinolin-5-ium chloride 
• 1218987-72-4 1-(cyclohexylamino)-2-phenyl-4-p-tolylpyrimido[6,1-a]isoquinolin-5-ium chloride 
• 201992-67-8 1-(N-Benzyl-p-methylbenzimidoyl)-3-(p-methoxyphenyl)thiourea 

Relevant academic research and scientific papers

New synthesis of 3-(β-D-glucopyranosyl)-5-substituted-1,2,4-triazoles, nanomolar inhibitors of glycogen phosphorylase

O-Perbenzoylated 5-(β-D-glucopyranosyl)tetrazole was reacted with N-benzyl carboximidoyl chlorides to give the corresponding 4-benzyl-3-(β-D- glucopyranosyl)-5-substituted-1,2,4-triazoles. Removal of the O-benzoyl and N-benzyl protecting groups by base catalysed transesterification and catalytic hydrogenation, respectively, furnished a series of 3-(β-D-glucopyranosyl)- 5-substituted-1,2,4-triazoles with aliphatic, mono- and bicyclic aromatic, and heterocyclic substituents in the 5-position. Enzyme kinetic studies revealed these compounds to inhibit rabbit muscle glycogen phosphorylase b: best inhibitors were the 5-(4-aminophenyl)- (Ki 0.67 μM) and the 5-(2-naphthyl)-substituted (Ki 0.41 μM) derivatives. This study uncovered the C-glucopyranosyl-1,2,4-triazoles as a novel skeleton for nanomolar inhibition of glycogen phosphorylase.

GLYCOGEN PHOSPHORYLASE INHIBITORS

The invention relates to compounds of formula (I) and stereoisomers, tautomers and pharmaceutically acceptable salts thereof and processes for preparing them. In formula (I) X is -CH= or -N= or -N(R") -; Y is -N= or -N(R") -; R is an alkyl group, an aryl group or a heteroaryl group, which groups are unsubstituted or substituted; R' is hydrogen or PG1, R" is hydrogen or PG2, R"' is hydrogen or R'OCH2-; n is an integer of 1 to 3. The invention also relates to pharmaceutical compositions containing these compounds. The compounds according to the invention are glycogen phosphorylase inhibitors and can be used e.g. for the treatment of type 2 diabetes, cardiovascular disorders and tumorous growth.˙

Parallel copper catalysis: Diastereoselective synthesis of polyfunctionalized azetidin-2-imines

An efficient and diastereoselective synthesis of highly functionalized azetidin-2-imines has been achieved through a parallel catalysis strategy, including a copper-catalyzed azide-alkyne cycloaddition, a copper-catalyzed Csp-Csp2 cr

Tandem synthesis of 1-(alkylamino)-2,4-diarylpyrimido[6,1-a]isoquinolin-5-ium chlorides from isoquinoline, N-alkyl-benzimidoyl chlorides, and isocyanides

1-(Alkylamino)-2,4-diarylpyrimido[6,1-a]isoquinolin-5-ium chlorides are obtained in good yields via a tandem reaction between isoquinoline, N-alkyl-benzimidoyl chlorides and alkyl isocyanides in anhydrous acetonitrile.